These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 26893546)

  • 1. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
    Cuffari C; Pierce D; Korczowski B; Fyderek K; Van Heusen H; Hossack S; Wan H; Edwards AY; Martin P
    Drug Des Devel Ther; 2016; 10():593-607. PubMed ID: 26893546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G; Florholmen J
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
    Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
    Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
    Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
    J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mesalazine old and new].
    Mañosa M; Domènech E
    Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():25-9. PubMed ID: 25443223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study.
    Vande Casteele N; Jakate A; McNamee B; Sandborn WJ
    Br J Clin Pharmacol; 2021 Mar; 87(3):1141-1149. PubMed ID: 32671846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
    Karamanolis DG; Papatheodoridis GV; Xourgias V
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
    Yarlas A; D'Haens G; Willian MK; Teynor M
    Inflamm Bowel Dis; 2018 Jan; 24(2):450-463. PubMed ID: 29361097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
    Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
    Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
    Horst SN; Kane S
    Expert Opin Pharmacother; 2012 Oct; 13(15):2225-32. PubMed ID: 22970981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.
    Winter HS; Krzeski P; Heyman MB; Ibarguen-Secchia E; Iwanczak B; Kaczmarski M; Kierkus J; Kolaček S; Osuntokun B; Quiros JA; Shah M; Yacyshyn B; Dunnmon PM
    J Pediatr Gastroenterol Nutr; 2014 Dec; 59(6):767-72. PubMed ID: 25419597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release mesalamine granules for ulcerative colitis.
    Love BL; Miller AD
    Ann Pharmacother; 2012 Nov; 46(11):1529-36. PubMed ID: 23115226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.